Page 1

arrowhead pharmaceuticals Arrowhead Pharmaceuticals Reports Fiscal 2021 Second Quarter Results May 4 , 2021 Conference Call and Webcast Today , May 4 , 2021 at 4:30 p.m. ET PASADENA , Calif .-- ( BUSINESS WIRE ) -- May 4 , 2021-- Arrowhead Pharmaceuticals , Inc. ( NASDAQ : ARWR ) today announced financial results for its fiscal second quarter ended March 31 , 2021. The company is hosting a conference call today , May 4 , 2021 , at 4:30 p.m. ET to discuss the results . Conference Call and Webcast Details Investors may access a live audio webcast on the Company's website at http://ir.arrowheadpharma.com/events.cfm . For analysts that wish to participate in the conference call , please dial 855-215-6159 or 315-625-6887 and provide Conference ID 3080187 . A replay of the webcast will be available on the company's website approximately two hours after the conclusion of the call and will remain available for 90 days . An audio replay will also be available approximately two hours after the conclusion of the call and will be available for 3 days . To access the audio replay , dial 855-859-2056 or 404-537-3406 and provide Conference ID 3080187 . Selected Recent Events • Announced positive interim 48 - week liver biopsy results from the AROAAT2002 study , an open - label Phase 2 clinical study of ARO - AAT , the company's second generation investigational RNA interference ( RNAi ) therapeutic being co - developed with Takeda Pharmaceutical Company Limited as a treatment for the rare genetic liver disease associated with alpha - 1 antitrypsin deficiency ( AATD ) . The interim readout demonstrated that ARO - AAT treatment led to : • Consistent and substantial reduction in intra - hepatic mutant AAT protein ( Z - AAT ) , both Z - AAT monomer and Z - AAT polymer • Consistent decrease in histological globule burden o Improvements in fibrosis o Improvements in other relevant biomarkers of liver health • Arrowhead intends to present additional interim AROAAT2002 data at an upcoming medical congress , pending abstract acceptance . • Announced ARO - DUX4 , Arrowhead's first muscle targeted investigational RNAi therapeutic candidate to utilize its proprietary Targeted RNAi Molecule ( TRIMTM ) platform . ARO - DUX4 is designed to target the gene that encodes human double homeobox 4 ( DUX4 ) protein as a potential treatment for patients with facioscapulohumeral muscular dystrophy ( FSHD ) . • Submitted an Investigational New Drug Application ( IND ) to the U.S. Food and Drug Administration ( FDA ) for a Phase 2b dose - finding clinical study of ARO - ANG3 , the company's investigational RNAi therapeutic being developed as a treatment for patients with mixed dyslipidemia . • Submitted an IND to the FDA for a Phase 2b dose - finding clinical study of ARO - APOC3 , the company's investigational RNAi therapeutic being developed as a treatment for patients with hypertriglyceridemia . Selected Fiscal 2021 Second Quarter Financial Results ARROWHEAD PHARMACEUTICALS , INC . CONSOLIDATED CONDENSED FINANCIAL INFORMATION ( unaudited ) ( in thousands , except per share amounts ) Three months ended March 31 , Six months ended March 31 , OPERATING SUMMARY REVENUE OPERATING EXPENSES Research and development General and administrative expenses TOTAL OPERATING EXPENSES OPERATING INCOME ( LOSS ) 2021 2020 2021 2020 $ 32,811 $ 23,529 $ 54,113 $ 52,983 44,697 29,443 81,251 52,817 16,346 16,326 25,147 27,260 61,043 45,769 106,398 80,077 ( 28,232 ) ( 22,240 ) ( 52,285 ) ( 27,094 ) OTHER INCOME / ( EXPENSE ) 1,414 NET INCOME ( LOSS ) $ ( 26,818 ) $ 2,404 ( 19,836 ) $ 4,735 4,585 ( 47,550 ) $ ( 22,509 ) NET INCOME ( LOSS ) PER SHARE ( DILUTED ) $ ( 0.26 ) $ ( 0.20 ) $ ( 0.46 ) $ ( 0.23 )